Table 4.
Results for voxel-based SDM meta-analysis of placebo controlled fMRI studies employing acute OXT challenge in humans*
| Group | Peak Talairach x, y, z | Z score | p value | Cluster voxels | Breakdown |
|---|---|---|---|---|---|
| OXT > PBO | |||||
| Left insula (extending to superior temporal gyrus and precentral frontal gyrus) | −46,−6,−6 | 2.451 | < 0.001 | 1182 | Left BA 13 (222) |
| Left BA 22 (219) | |||||
| Left BA 38 (174) | |||||
| Left BA 6 (165) | |||||
| Left BA 21 (120) | |||||
| Left BA 43 (70) | |||||
| Left BA 44 (39) | |||||
| Left BA 4 (37) | |||||
| Left BA 47 (31) | |||||
| Left BA 42 (26) | |||||
| Left BA 9 (19) | |||||
| Left BA 20 (12) | |||||
| OXT < PBO | — | — | — | — | — |
BA = Brodmann area; OXT = oxytocin; PBO = placebo; SDM = signed differential mapping.
*
Results were thresholded with voxel p ≤ 0.005, uncorrected; peak z ≥ 2; and cluster extent ≥ 10 voxels. Breakdown regions with an extent < 10 voxels extent are not reported.